Close Menu

gene editing

Novartis looks toward employing the CRISPR genome-editing tool to develop new therapeutics and as a research tool.

The arrangement covers Cellectis' TALEN technology and Two Blades' TAL effector code technology.

Technology Review examines who owns the CRISPR/Cas9 gene editing approach.

The licenses provide non-exclusive access to the IP for research applications.

NEW YORK (GenomeWeb) – Researchers from New York University Langone School of Medicine have developed a synthetic biology method to linearize circular DNA molecules in vivo.

NEW YORK (GenomeWeb) – Clontech Laboratories today announced a non-exclusive licensing deal with the Broad Institute for its CRISPR-Cas9 technology.

NEW YORK (GenomeWeb) – Horizon Discovery Group today announced the acquisition of Sage Labs, a provider of research models and transgenic support services, for up to $48 million.

NEW YORK (GenomeWeb) – Kultevat today said it has exclusively licensed technology to control plant gene expression from the Donald Danforth Plant Science Center.

NEW YORK (GenomeWeb) – Horizon Discovery today announced that its CombinatoRx division has entered into a contract with Otsuka Pharmaceutical Development and Commercialization to perform in vitro cell line screening of certain OPDC candidates in development.

NEW YORK (GenomeWeb) – Horizon Discovery today announced a non-exclusive deal to license intellectual property from Stanford University related to the use of a proprietary serotype of adeno-associated virus for commercial applications involving homologous recombination in gene editing.

Pages

In PLOS this week: transcriptomic and genomic analysis of prostate cancer by ancestry, genes linked to liver function in Korean cohort, and more.

British Columbia is incorporating genomics into its tracking of the ongoing COVID-19 outbreak, Business in Vancouver reports.

An analysis by the Personalized Medicine Coalition finds that about a quarter of new drugs approved in 2019 by the US Food and Drug Administration were personalized medicines.

The governor of New York has proposed a five-year plan to study the genomes of people with or who are at high risk of developing Alzheimer's disease.